Consolidated statement of income
Download(XLS, 47 KB)| € in millions | Note | 2023 | 2022 restated¹ | 2022 previous |
|---|---|---|---|---|
| Revenue | 4 | 22,299 | 21,532 | 40,840 |
| Costs of revenue | -17,241 | -16,129 | -30,531 | |
| Gross profit | 5,058 | 5,403 | 10,309 | |
| Selling expenses | -750 | -746 | -2,323 | |
| General and administrative expenses | 8 | -2,405 | -2,348 | -3,853 |
| Other operating income | 9 | 402 | 353 | 529 |
| Other operating expenses | 9 | -501 | -211 | -474 |
| Research and development expenses | 7 | -661 | -639 | -867 |
| Operating income (EBIT) | 1,143 | 1,812 | 3,321 | |
| Income from the Fresenius Medical Care investment accounted for using the equity method | 21 | -12 | n.a. | n.a. |
| Interest income | 10 | 118 | 130 | 187 |
| Interest expenses | 10 | -534 | -345 | -694 |
| Income before income taxes | 715 | 1,597 | 2,814 | |
| Income taxes | 11 | -477 | -375 | -697 |
| Net income from continuing operations | 238 | 1,222 | 2,117 | |
| Noncontrolling interests in continuing operations | 12 | -115 | 68 | 745 |
| Net income from continuing operations attributable to shareholders of Fresenius SE & Co. KGaA | 353 | 1,154 | 1,372 | |
| Net income from deconsolidated Fresenius Medical Care operations under IFRS 5 | -1,938 | 895 | n.a. | |
| Noncontrolling interests in deconsolidated Fresenius Medical Care operations under IFRS 5 | -991 | 677 | n.a. | |
| Net income from deconsolidated Fresenius Medical Care operations under IFRS 5 attributable to shareholders of Fresenius SE & Co. KGaA | -947 | 218 | n.a. | |
| Net income | -1,700 | 2,117 | 2,117 | |
| Noncontrolling interests in net income | -1,106 | 745 | 745 | |
| Net income attributable to shareholders of Fresenius SE & Co. KGaA | -594 | 1,372 | 1,372 | |
| Earnings per share in € (basic and diluted) | 14 | -1.05 | 2.44 | 2.44 |
| thereof based on net income from continuing operations | 0.63 | 2.05 | 2.44 | |
| thereof based on net income from deconsolidated Fresenius Medical Care operations under IFRS 5 | -1.68 | 0.39 | n.a. | |
| 1 Prior-year figures have been adjusted due to the application of IFRS 5 to the deconsolidated operations of Fresenius Medical Care. |
||||
| The following notes are an integral part of the consolidated financial statements. | ||||
Contact
Fresenius SE & Co. KGaA
Investor Relations
+49 (0) 6172 608-2485
ir-fre@fresenius.com